$187 Million is the total value of Kynam Capital Management, LP's 32 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $29,064,000 | – | 992,949 | +100.0% | 15.54% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $20,934,000 | – | 670,093 | +100.0% | 11.19% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $20,930,000 | – | 956,165 | +100.0% | 11.19% | – |
| GOSS | New | GOSSAMER BIO INC | $11,501,000 | – | 1,016,857 | +100.0% | 6.15% | – |
| BIIB | New | BIOGEN INC | $9,597,000 | – | 40,000 | +100.0% | 5.13% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $8,761,000 | – | 226,726 | +100.0% | 4.68% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $7,451,000 | – | 2,210,866 | +100.0% | 3.98% | – |
| VERA | New | VERA THERAPEUTICS INCcl a | $6,772,000 | – | 253,449 | +100.0% | 3.62% | – |
| LQDA | New | LIQUIDIA CORPORATION | $6,656,000 | – | 1,366,836 | +100.0% | 3.56% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $6,626,000 | – | 573,699 | +100.0% | 3.54% | – |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $5,692,000 | – | 287,934 | +100.0% | 3.04% | – |
| TVTX | New | TRAVERE THERAPEUTICS INC | $5,652,000 | – | 182,103 | +100.0% | 3.02% | – |
| FATE | New | FATE THERAPEUTICS INC | $5,591,000 | – | 95,561 | +100.0% | 2.99% | – |
| PCVX | New | VAXCYTE INC | $5,031,000 | – | 211,483 | +100.0% | 2.69% | – |
| WVE | New | WAVE LIFE SCIENCES LTD | $4,693,000 | – | 1,494,594 | +100.0% | 2.51% | – |
| MRUS | New | MERUS N V | $3,885,000 | – | 122,158 | +100.0% | 2.08% | – |
| BNR | New | BURNING ROCK BIOTECH LTDsponsored ads | $3,645,000 | – | 382,464 | +100.0% | 1.95% | – |
| ZGNX | New | ZOGENIX INC | $3,344,000 | – | 205,800 | +100.0% | 1.79% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $2,750,000 | – | 293,799 | +100.0% | 1.47% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,692,000 | – | 239,041 | +100.0% | 1.44% | – |
| MCRB | New | SERES THERAPEUTICS INC | $2,540,000 | – | 304,901 | +100.0% | 1.36% | – |
| CABA | New | CABALETTA BIO INC | $2,443,000 | – | 644,583 | +100.0% | 1.31% | – |
| KRYS | New | KRYSTAL BIOTECH INC | $2,435,000 | – | 34,816 | +100.0% | 1.30% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $2,078,000 | – | 683,619 | +100.0% | 1.11% | – |
| AFMD | New | AFFIMED N V | $2,009,000 | – | 364,033 | +100.0% | 1.07% | – |
| RDUS | New | RADIUS HEALTH INC | $1,343,000 | – | 194,082 | +100.0% | 0.72% | – |
| COGT | New | COGENT BIOSCIENCES INC | $1,287,000 | – | 150,000 | +100.0% | 0.69% | – |
| AKUS | New | AKOUOS INC | $842,000 | – | 99,008 | +100.0% | 0.45% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $709,000 | – | 147,000 | +100.0% | 0.38% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $101,000 | – | 110,991 | +100.0% | 0.05% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $15,000 | – | 100,000 | +100.0% | 0.01% | – |
| ALLK | New | ALLAKOS INCcall | $2,000 | – | 74,500 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.